[Back to Issue 11 ToC] [Back to Journal Contents] [Back to Biochemistry (Moscow) Home page]
[View Full Article] [Download Reprint (PDF)]

REVIEW: Inhibitors of β-Lactamases. New Life of β-Lactam Antibiotics

A. M. Egorov1, M. M. Ulyashova1, and M. Yu. Rubtsova1,a*

1Faculty of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia

* To whom correspondence should be addressed.

Received July 9, 2020; Revised August 14, 2020; Accepted August 15, 2020
β-Lactam antibiotics account for about 60% of all produced antibiotics. Due to a high activity and minimal side effects, they are the most commonly used class of antibacterial drugs for the treatment of various infectious diseases of humans and animals, including severe hospital infections. However, the emergence of bacteria resistant to β-lactams has led to the clinical inefficiency of these antibiotics, and as a result, their use in medicine has been limited. The search for new effective ways for overcoming the resistance to β-lactam antibiotics is an essential task. The major mechanism of bacterial resistance is the synthesis of β-lactamases (BLs) that break the antibiotic β-lactam ring. Here, we review specific inhibitors of serine β-lactamases and metallo-β-lactamases and discuss approaches for creating new inhibitors that would prolong the “life” of β-lactams.
KEY WORDS: antibiotic resistance of bacteria, β-lactamases, inhibitors, β-lactam antibiotics

DOI: 10.1134/S0006297920110024